ZIB

Digitale Medien

Does atenolol improve physical and psychological function after coronary artery bypass surgery: A controlled study

Bass, C. ; Akhras, F. ; Upward, J. ; [weitere]

Amsterdam : Elsevier

Journal of Psychosomatic Research 31 (1987), S. 521-529

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 0022-3999

Quelle: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002

Thema: Medizin , Psychologie

Materialart: Digitale Medien

URL: http://linkinghub.elsevier.com/retrieve/pii/0022-3999(87)90010-9

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

The appropriate dosage regime for the transition from intravenous lignocaine to oral tocainide after acute myocardial infarction (1983)

Upward, J. W. ; Holt, D. ; Emery, P. ; [weitere]

Springer

European journal of clinical pharmacology 25 (1983), S. 589-594

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-1041

Schlagwort(e): Tocainide ; Lignocaine

Quelle: Springer Online Journal Archives 1860-2000

Thema: Chemie und Pharmazie , Medizin

Notizen: Summary To define the appropriate regime for the transition from intravenous lignocaine to oral tocainide after uncomplicated acute myocardial infarction, 43 patients received lignocaine to steady state. Each patient then received a tocainide dosage schedule. Plasma concentration of lignocaine and tocainide was measured frequently until the third peak plasma tocainide level. Tocainide 400 mg 8 hourly starting 4 h before cessation of lignocaine and tocainide 400 mg 4 hourly starting at the end of the infusion produced therapeutic plasma tocainide concentration (3.5–9 mg/l) only after the second dose. Tocainide 600 mg 12 hourly starting 6 h before cessation of lignocaine and tocainide 600 mg 6 hourly starting at the end of the infusion quickly achieved therapeutic plasma tocainide concentration which declined to give subtherapeutic first dose troughs of 2.42 mg/l (±0.28 SEM) and 2.79 mg/l (±0.27 SEM) respectively. Consistently therapeutic plasma tocainide concentrations were achieved by both of these regimes after the second dose. The short plasma halflife of lignocaine which for these regimes was 3.71 h (±0.25 SEM), resulted in subtherapeutic lignocaine concentrations before consistently therapeutic plasma tocainide concentrations had been achieved. On the basis of these results, the 600 mg 6 hourly tocainide dosage schedule was studied with cessation of lignocaine infusion either two or six h after the first tocainide dose. With the former regime only three of 5 patients had therapeutic lignocaine at the subtherapeutic tocainide trough. When lignocaine was discontinued on administration of the second tocainide dose however, therapeutic lignocaine concentration was maintained in all patients until tocainide was rising within the therapeutic range. The latter regime, which we would recommend, was not accompanied by increased side effects. Steady state tocainide was found to be present 12 h after the third tocainide dose allowing continued therapy with tocainide 600 mg 12 hourly.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF00542344

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

Pharmacokinetics and tolerability of ascending intravenous doses of granisetron, a novel 5-HT3 antagonist, in healthy human subjects (1994)

Allen, A. ; Asgill, C. C. ; Pierce, D. M. ; [weitere]

Springer

European journal of clinical pharmacology 46 (1994), S. 159-162

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-1041

Schlagwort(e): Granisetron ; Anti-emetic ; pharmacokinetics ; tolerance ; ascending dose ; healthy subjects

Quelle: Springer Online Journal Archives 1860-2000

Thema: Chemie und Pharmazie , Medizin

Notizen: Abstract The pharmacokinetics and tolerance of granisetron, a novel 5HT3-receptor antagonist which is under development as an anti-emetic agent have been studied after administration of single 30 min intravenous infusions to three groups of 8 healthy male subjects, in a series of placebo-controlled ascending dose studies (50, 80, 100 and 130 μg·kg−1 to group 1; 150, 180, 200 and 230 μg·kg−1 to group 2 and 270 and 300 μg·kg−1 to group 3). Plasma and urine samples were analysed for granisetron by HPLC with fluorimetric detection. Administration of granisetron was well tolerated by the volunteers and there were no serious adverse effects reported. Pharmacokinetic parameters and dose-normalised plasma levels appeared to be independent of dose in the range 50 to 300 μg·kg−1, although there was extensive inter-subject variability. Granisetron was extensively distributed, with mean volumes of distribution ranging from 186–264 l at the various doses. Total plasma clearance was, in general, rapid (mean values of 37.0 to 49.9 l·h−1) and predominantly non-renal, with most subjects excreting less than 20% of the dose unchanged in urine. Mean t1/2 values ranged from 4.1 to 6.3 h and MRT from 5.2 to 8.1 h.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF00199881

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers (1996)

Brocks, D. R. ; Upward, J. W. ; Georgiou, P. ; [weitere]

Springer

European journal of clinical pharmacology 51 (1996), S. 303-308

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-1041

Schlagwort(e): Key words Pranlukast ; Asthma bronchial; pharmacokinetics ; leukotriene antagonist

Quelle: Springer Online Journal Archives 1860-2000

Thema: Chemie und Pharmazie , Medizin

Notizen: Abstract Objective: The pharmacokinetics of pranlukast, a leukotriene LTD4 antagonist, were studied in 48 young, healthy subjects after single and repeated oral doses (given every 12 h) ranging from 112.5 to 675 mg. The doses were administered 30 minutes after a light breakfast. Results: Maximal drug concentrations generally occurred between 2 and 6 h after dosing, and there was some evidence of an absorption lag-time. Secondary peaks were observed in the plasma concentration vs. time profiles of many of the study subjects after both single and repeated doses, particularly during the period of maximum drug absorption. In general, after both single and repeated doses, there were related increases in the corresponding Cmax and AUC with a rise in dose, although the increase was diminished at doses above 450 mg. With repeated dosing of pranlukast the mean AUC was generally higher (up to 1.6-fold), and the higher plasma concentrations allowed characterisation of a longer mean t1/2 than after single dose administration. The mean steady-state trough plasma concentrations attained after evening doses were considerably higher (up to 14-fold) than those obtained after the morning dose. Conclusion: The data suggested that the pharmacokinetics of pranlukast are influenced by the time of dosing. Based on analysis of urinary 6β-hydroxycortisol excretion, there was no evidence that pranlukast modified the metabolic activity of cytochrome P-450 3A isoenzymes.

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/s002280050202

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Digitale Medien

The pharmacokinetics of granisetron, a 5-HT3 antagonist in healthy young and elderly volunteers (1995)

Allen, A. ; Davie, C. C. ; Pierce, D. M. ; [weitere]

Springer

European journal of clinical pharmacology 48 (1995), S. 519-520

zur Merkliste hinzufügen auf der Merkliste

Details

ISSN: 1432-1041

Schlagwort(e): Granisetron ; pharmacokinetics ; elderly ; tolerance

Quelle: Springer Online Journal Archives 1860-2000

Thema: Chemie und Pharmazie , Medizin

Materialart: Digitale Medien

URL: http://dx.doi.org/10.1007/BF00194344

Permalink

Bibliothek	Standort	Signatur	Band/Heft/Jahr	Verfügbarkeit

Andere fanden auch interessant ...

Artikel (Nationallizenzen)

Volltext

Treffer 1 - 5 | 5 Treffer